Literature DB >> 18303260

Malaria parasitemia associated with febrile neutropenia in African patients undergoing chemotherapy for haematological malignancies. A report of three patients.

Bernardo L Rapoport1, Almarie Uys.   

Abstract

BACKGROUND: Very little is documented in the medical literature on the association between malaria parasitemia and febrile neutropenia in patients undergoing cancer chemotherapy.
METHODS: This report will concentrate on the clinical presentation and outcome of 3 patients with haematological malignancies undergoing chemotherapy who developed febrile neutropenia and malaria parasitemia concurrently.
RESULTS: Three patients infected with documented malaria during a febrile neutropenic episode are presented. Two patients (1 with Hodgkin's disease and the other with non-Hodgkin's lymphoma) were successfully treated and are alive after a follow-up period of 120 and 90 months, respectively. A third patient with acute lymphoblastic leukaemia developed renal failure as a complicating factor of malaria and died.
CONCLUSION: It is suggested that malaria should be considered as a possible cause or a complicating factor of febrile neutropenia in patients undergoing cancer chemotherapy in endemic malaria areas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18303260     DOI: 10.1159/000118663

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  2 in total

1.  Malaria hidden in a patient with diffuse large-B-cell lymphoma and sickle-cell trait.

Authors:  María Linares; Enriqueta Albizua; Darío Méndez; José M Rubio; Alejandra Martínez-Serna; Miguel A Martínez; Efren Salto; Antonio Puyet; Amalia Diez; Joaquin Martinez-López; José M Bautista
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

Review 2.  Malaria and Cancer: a critical review on the established associations and new perspectives.

Authors:  Toby Ellis; Elvis Eze; Bahijja Tolulope Raimi-Abraham
Journal:  Infect Agent Cancer       Date:  2021-05-13       Impact factor: 2.965

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.